AbbVie plans to present data from 38 abstracts of Humira (adalimumab) and other products in the company’s investigational immunology medicine portfolio at the 2017 American College of Rheumatology (ACR)/Association for Rheumatology Health Professionals (ARHP) annual meeting Nov. 3-8, in San Diego.
"Building on more than two decades of clinical trial experience with Humira, AbbVie's body of research reinforces our commitment to developing treatment options for people living with immune-mediated inflammatory diseases," Dr. Shao-Lee Lin, vice president for therapeutic areas and international development at AbbVie, said in a release. "We look forward to sharing new developments that illustrate our patient-centered approach to treating rheumatic conditions, and the depth and breadth of AbbVie's portfolio."
Abstracts to be presented include a long-term safety and efficacy study of Upadacitini for treating rheumatoid arthritis, results from a Phase 2 trial of Risankizumab for treating psoriatic arthritis and a long-term safety study of adalimumab for treating rheumatoid arthritis, the release said.
